Loading
A phase 3 trial of Camizestrant and Ribociclib in HR-positive / HER2-negative breast cancer, run by AstraZeneca, now recruiting.
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer is a phase 3 interventional study registered as NCT07647328 by AstraZeneca, with 150 participants planned, started 2026-06-15 and due to reach its primary completion in 2029-02-28. Interventions recorded: Camizestrant and Ribociclib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Camizestrant, CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs), AstraZeneca and the tag pipeline.
Shares Camizestrant, CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs), AstraZeneca and the tag pipeline.
Shares Camizestrant, Ribociclib, Endocrine therapy (SERMs, AIs, SERDs), AstraZeneca and the tag pipeline.
Shares Camizestrant, Endocrine therapy (SERMs, AIs, SERDs), AstraZeneca, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares ICON plc and the tag pipeline.
Shares Camizestrant, Endocrine therapy (SERMs, AIs, SERDs), AstraZeneca and the tag pipeline.
Shares Endocrine therapy (SERMs, AIs, SERDs), AstraZeneca, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Ribociclib, CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/